Publication

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

GENEPSO, EMBRACE, HEBON, kConFab Investigators, IBCCS, kConFab, BCFR, Mavaddat, N., Antoniou, A. C., Mooij, T. M., Hooning, M. J., Heemskerk-Gerritsen, B. A., Nogues, C. & Gauthier-Villars, M., 16-Jan-2020, In : Breast cancer research. 22, 1, 11 p., 8.

Research output: Contribution to journalArticleAcademicpeer-review

APA

GENEPSO, EMBRACE, HEBON, kConFab Investigators, IBCCS, kConFab, BCFR, Mavaddat, N., Antoniou, A. C., Mooij, T. M., Hooning, M. J., Heemskerk-Gerritsen, B. A., Nogues, C., & Gauthier-Villars, M. (2020). Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast cancer research, 22(1), [8]. https://doi.org/10.1186/s13058-020-1247-4

Author

GENEPSO ; EMBRACE ; HEBON ; kConFab Investigators ; IBCCS ; kConFab ; BCFR ; Mavaddat, Nasim ; Antoniou, Antonis C. ; Mooij, Thea M. ; Hooning, Maartje J. ; Heemskerk-Gerritsen, Bernadette A. ; Nogues, Catherine ; Gauthier-Villars, Marion. / Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk : an international prospective cohort of BRCA1 and BRCA2 mutation carriers. In: Breast cancer research. 2020 ; Vol. 22, No. 1.

Harvard

GENEPSO, EMBRACE, HEBON, kConFab Investigators, IBCCS, kConFab, BCFR, Mavaddat, N, Antoniou, AC, Mooij, TM, Hooning, MJ, Heemskerk-Gerritsen, BA, Nogues, C & Gauthier-Villars, M 2020, 'Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers', Breast cancer research, vol. 22, no. 1, 8. https://doi.org/10.1186/s13058-020-1247-4

Standard

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk : an international prospective cohort of BRCA1 and BRCA2 mutation carriers. / GENEPSO; EMBRACE; HEBON; kConFab Investigators; IBCCS; kConFab; BCFR; Mavaddat, Nasim; Antoniou, Antonis C.; Mooij, Thea M.; Hooning, Maartje J.; Heemskerk-Gerritsen, Bernadette A.; Nogues, Catherine; Gauthier-Villars, Marion.

In: Breast cancer research, Vol. 22, No. 1, 8, 16.01.2020.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

GENEPSO, EMBRACE, HEBON, kConFab Investigators, IBCCS, kConFab et al. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast cancer research. 2020 Jan 16;22(1). 8. https://doi.org/10.1186/s13058-020-1247-4


BibTeX

@article{efde3142ef4b4bdf867bcffa48df61e6,
title = "Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers",
abstract = "Background The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Methods A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Results There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.",
keywords = "Breast cancer, BRCA1, BRCA2, Mutation, Risk-reducing salpingo-oophorectomy, WOMEN, METAANALYSIS, ASSOCIATION, CONSORTIUM, REDUCTION, SURVIVAL, KCONFAB, SURGERY, OVARIAN, LINK",
author = "GENEPSO and EMBRACE and HEBON and {kConFab Investigators} and IBCCS and kConFab and BCFR and Nasim Mavaddat and Antoniou, {Antonis C.} and Mooij, {Thea M.} and Hooning, {Maartje J.} and Heemskerk-Gerritsen, {Bernadette A.} and Catherine Nogues and Marion Gauthier-Villars and Lilian Laborde and Emmanuel Breysse and Dominique Stoppa-Lyonnet and Bruno Buecher and Olivier Caron and Emmanuelle Fourme-Mouret and Jean-Pierre Fricker and Christine Lasset and Valerie Bonadona and Pascaline Berthet and Laurence Faivre and Elisabeth Luporsi and Veronique Mari and Laurence Gladieff and Paul Gesta and Hagay Sobol and Francois Eisinger and Catherine Nogues and Michel Longy and Catherine Dugast and Chrystelle Colas and Isabelle Coupier and Pascal Pujol and Carole Corsini and Alain Lortholary and Philippe Vennin and Claude Adenis and Nguyen, {Tan Dat} and Capucine Delnatte and Julie Tinat and Isabelle Tennevet and Jean-Marc Limacher and Christine Maugard and Yves-Jean Bignon and Liliane Demange and Clotilde Penet and Helene Dreyfus and Odile Cohen-Haguenauer and Laurence Venat-Bouvet and Mensenkamp, {A. R.} and Blok, {M. J.} and Oosterwijk, {J. C.} and Mourits, {Marian J. E.}",
year = "2020",
month = jan,
day = "16",
doi = "10.1186/s13058-020-1247-4",
language = "English",
volume = "22",
journal = "Breast cancer research",
issn = "1465-5411",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk

T2 - an international prospective cohort of BRCA1 and BRCA2 mutation carriers

AU - GENEPSO

AU - EMBRACE

AU - HEBON

AU - kConFab Investigators

AU - IBCCS

AU - kConFab

AU - BCFR

AU - Mavaddat, Nasim

AU - Antoniou, Antonis C.

AU - Mooij, Thea M.

AU - Hooning, Maartje J.

AU - Heemskerk-Gerritsen, Bernadette A.

AU - Nogues, Catherine

AU - Gauthier-Villars, Marion

AU - Laborde, Lilian

AU - Breysse, Emmanuel

AU - Stoppa-Lyonnet, Dominique

AU - Buecher, Bruno

AU - Caron, Olivier

AU - Fourme-Mouret, Emmanuelle

AU - Fricker, Jean-Pierre

AU - Lasset, Christine

AU - Bonadona, Valerie

AU - Berthet, Pascaline

AU - Faivre, Laurence

AU - Luporsi, Elisabeth

AU - Mari, Veronique

AU - Gladieff, Laurence

AU - Gesta, Paul

AU - Sobol, Hagay

AU - Eisinger, Francois

AU - Nogues, Catherine

AU - Longy, Michel

AU - Dugast, Catherine

AU - Colas, Chrystelle

AU - Coupier, Isabelle

AU - Pujol, Pascal

AU - Corsini, Carole

AU - Lortholary, Alain

AU - Vennin, Philippe

AU - Adenis, Claude

AU - Nguyen, Tan Dat

AU - Delnatte, Capucine

AU - Tinat, Julie

AU - Tennevet, Isabelle

AU - Limacher, Jean-Marc

AU - Maugard, Christine

AU - Bignon, Yves-Jean

AU - Demange, Liliane

AU - Penet, Clotilde

AU - Dreyfus, Helene

AU - Cohen-Haguenauer, Odile

AU - Venat-Bouvet, Laurence

AU - Mensenkamp, A. R.

AU - Blok, M. J.

AU - Oosterwijk, J. C.

AU - Mourits, Marian J. E.

PY - 2020/1/16

Y1 - 2020/1/16

N2 - Background The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Methods A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Results There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.

AB - Background The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Methods A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Results There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.

KW - Breast cancer

KW - BRCA1

KW - BRCA2

KW - Mutation

KW - Risk-reducing salpingo-oophorectomy

KW - WOMEN

KW - METAANALYSIS

KW - ASSOCIATION

KW - CONSORTIUM

KW - REDUCTION

KW - SURVIVAL

KW - KCONFAB

KW - SURGERY

KW - OVARIAN

KW - LINK

U2 - 10.1186/s13058-020-1247-4

DO - 10.1186/s13058-020-1247-4

M3 - Article

VL - 22

JO - Breast cancer research

JF - Breast cancer research

SN - 1465-5411

IS - 1

M1 - 8

ER -

ID: 132894476